A New Generation of Medicines
Engineering cytokine mimetics
to change the course of serious diseases
A New Generation of Medicines
Engineering cytokine mimetics to change the course of serious diseases
A New Generation of Medicines
Engineering cytokine mimetics to change the course of serious diseases
Artwork by Seb Janiak, MIMESIS Series
Unique Advantages of PEPTIKINES
PEPTIKINESᵀᴹ are substantially smaller molecules than cytokines, making them readily amenable to enhancement for desired pharmacokinetics or added pharmacologic features, including cell targeting and conditional activation. Because PEPTIKINES are structurally unrelated to natural cytokines, they do not generate neutralizing antibodies to cytokines.
Who We Are
Medikine is led by an accomplished team of industry veterans with decades of experience in pioneering drug discovery technology and the clinical development of immuno-oncology therapeutics.
William J. Dower, PhD, Michael C. Needels, PhD, and Ronald W. Barrett, PhD have collaborated since the 1990’s, which led to their groundbreaking discovery of peptide mimetics of erythropoietin and thrombopoietin at the Affymax Research Institute. Accomplished immuno-oncology drug developer, Joseph Leveque, MD, who has been involved in the clinical development of checkpoint inhibitor, IL-2, IL-10, and IL-15 therapeutics, now leads Medikine in applying this expertise to the clinical development of optimized therapies based on cytokine mimesis.
Join Us
Up for a challenge with limitless possibilities? We would love to hear from you.